Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest Amylin Stories

2011-07-26 06:30:00

SAN DIEGO, July 26, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended June 30, 2011. Total revenue was $158.1 million for the quarter ended June 30, 2011, which included net product sales of $154.8 million Non-GAAP operating loss was $1.7 million, compared to $7.4 million for the same period in 2010 GAAP net loss was $31.4 million, or $0.22 per share, compared to $44.2 million, or $0.31 per share, for the same...

2011-07-19 15:15:00

SAN DIEGO, July 19, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the second quarter of 2011 on Tuesday, July 26, 2011 at 8:30 a.m. ET/5:30 a.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date pre-market, Amylin will release financial results for the second quarter of 2011. The call will be webcast live through the "Investors" section of Amylin's...

2011-07-12 12:39:47

New animal research demonstrates mechanisms that are involved in suppressing food intake and preventing obesity with exercise Research to be presented at the upcoming annual meeting of the Society for the Study of Ingestive Behavior (SSIB), the foremost society for research into all aspects of eating and drinking behavior, finds that alterations of meal-related gut hormone signals may contribute to the overall effects of exercise to help manage body weight. Regular exercise is important in...

2011-07-07 16:17:00

SAN DIEGO, INDIANAPOLIS, and WALTHAM, Mass., July 7, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results from a thorough QT (tQT) study that assessed the potential of exenatide to increase the QT interval across a wide range of plasma concentrations. The study was conducted to satisfy a requirement by the U.S. Food and Drug Administration (FDA) in support of the New Drug Application...

2011-07-01 13:08:50

In type 2 diabetes, a protein called amylin forms dense clumps that shut down insulin-producing cells, wreaking havoc on the control of blood sugar. But zinc has a knack for preventing amylin from misbehaving. Recent research at the University of Michigan offers new details about how zinc performs this "security guard" function. The findings appear in the July 8 issue of the Journal of Molecular Biology. Amylin is something of a two-faced character. In healthy people who have normal levels of...

2011-06-24 16:00:00

SAN DIEGO, June 24, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced data from a new analysis characterizing the effects of SYMLIN® (pramlintide acetate) injection in patients with type 1 diabetes who used insulin pumps during two previously completed clinical studies. The data, which will be presented during a poster presentation at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego, demonstrated that...

2011-06-24 16:00:00

SAN DIEGO, June 24, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results from an analysis of the DURATION-1 study that showed the investigational type 2 diabetes medication BYDUREON(TM) (exenatide extended-release for injectable suspension) was not associated with clinically relevant QT prolongation in patients with type 2 diabetes. These findings will be presented in a poster session...

2011-06-24 16:00:00

SAN DIEGO, June 24, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced additional results from a phase 2 study of an investigational, once-monthly injectable suspension formulation of exenatide which showed substantial improvements in glycemic control, including reductions in A1C and fasting plasma glucose, with modest weight loss. These findings will be presented in a late breaking poster...

2011-06-20 15:15:00

SAN DIEGO, June 20, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA® (exenatide) injection and SYMLIN® (pramlintide acetate) injection, and its investigational diabetes drug candidates BYDUREON(TM) (exenatide extended-release for injectable suspension) and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes...

2011-06-08 15:17:00

INDIANAPOLIS, June 8, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the Southern District of California ruled in Lilly's favor, vacating a temporary restraining order and denying a request by Amylin Pharmaceuticals for a preliminary injunction that sought to impose restrictions on the Lilly Diabetes sales force and other relief. Amylin recently filed litigation involving the two companies' diabetes collaboration agreement. "We are...